Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

142.66 +0.17 (+0.12%)
Streaming Delayed Price Updated: 2:49 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
49 50 Next >
Novo Nordisk Skyrockets To $506B Valuation Driven By 'Miracle' Drugs Ozempic, Wegovy
The company predicts a sales growth of 18% to 26% in CER terms for the current year, driven by the soaring demand for Wegovy and Ozempic, which contain the same active ingredient. 
Via Benzinga
Earnings Preview: Novo Nordisk
Via Benzinga
Will Novo Nordisk Be a $1 Trillion Company by 2030?
Novo Nordisk's market cap has ballooned thanks to the overwhelming success of its Ozempic, Wegovy, and Rybelsus medications. 
Via The Motley Fool
Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government
Eli Lilly in talks with German government to lift ban on health system coverage for weight-loss treatments. Explore Mounjaro's recent EU approval and market launches. 
Via Benzinga
Forget The Magnificent Seven. Focus On These Fab Five.
Investors put a lot of attention on Nvidia and the rest of the Magnificent Seven. But two of these S&P 500 giants aren't fabulous. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Investors seeking growth at a reasonable cost should explore NYSE:NVO.
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) is showing decent growth, but is still valued reasonably. 
Via Chartmill
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Earnings Scheduled For January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion. 
Via Benzinga
Market Whales and Their Recent Bets on NVO Options
Via Benzinga
If You Invested $5,000 in Novo Nordisk in 2019, This Is How Much You Would Have Today
The answer may surprise you. 
Via The Motley Fool
Could Eli Lilly Be a Trillion-Dollar Company by 2030?
Eli Lilly is the world's largest healthcare company by market cap, and the 10th most valuable business in the world. 
Via The Motley Fool
Eli Lilly's Famed Obesity And Diabetes Drug, Mounjaro, Comes To UK Patients, Wins Regulatory Clearance For Prefilled Injection Pen
Eli Lilly's MHRA-approved Mounjaro KwikPen offers effective diabetes and weight management. Learn about the four-dose version's benefits for type 2 diabetes patients. 
Via Benzinga
5 Mega-Cap Stocks Ready to Make the Magnificent 7 a Dynamic Dozen
With mega-cap stocks setting new highs, here are five new names that could take the Magnificent 7 to a Dynamic Dozen. 
Via InvestorPlace
5 top healthcare stocks for earnings growth in 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed. 
Via MarketBeat
Is Novo Nordisk Stock a Buy Now?
The biotech is on a roll, and that won't end soon. 
Via The Motley Fool
Check Out What Whales Are Doing With NVO
Via Benzinga
Weight Loss Drug's Ozempic Counterfeit: Rising Reports Over Patient Safety Related Fake Drugs
Discover the alarming rise in fake Ozempic cases, leading to hypoglycemia. Learn about FDA investigations, counterfeit warnings, and the surge in reports. 
Via Benzinga
Exposures Product Safety
Jim Cramer Says Eli Lilly Could Replace Tesla In 'Magnificent Seven' List: 'To Ignore...Is To Reject The Facts'
Jim Cramer has hinted at the possibility of Tesla being replaced by Eli Lilly in the "Magnificent Seven" list of mega-cap stocks. 
Via Benzinga
3 Phenomenal Stock-Split Stocks You Should Be Buying Now
Because the market sees stock splits as a sign of future growth these stock-split stocks could be tomorrow's winners. 
Via InvestorPlace
European Drug Regulator To Consider Expanded Use Of Novo Nordisk's Wegovy Weight-Loss Drug
EMA's discussions on extending Novo Nordisk's Wegovy for reducing stroke and heart attack risks. SELECT trial results support its integration into public health systems. 
Via Benzinga
Why Novo Nordisk Stock Soared 53% in 2023 (Hint: It Wasn't Just Ozempic)
Last year was one for the history books for the Danish drugmaker. 
Via The Motley Fool
Got $1,000? 3 Growth Stocks to Buy That Could Double Your Money
Healthcare is nearly a fifth of America's economy. Ride these high-flying healthcare stocks to monster gains. 
Via The Motley Fool
Topics Economy
Exposures Economy
3 High-Flying Stocks That Could Soar Even More in 2024
These big winners could keep the momentum going. 
Via The Motley Fool
Weightloss Drugs Ozempic And Wegovy's Success Sets Novo Nordisk's Owner To Utilize Dividend Windfall For Strategic Investments
Explore Novo Holdings' 2024 plans for acquisitions and investments in Asia, led by CEO Kasim Kutay. Discover strategic initiatives, global studies on NVO drugs, and insights into challenges and... 
Via Benzinga
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. 
Via MarketBeat
These 2 Top Healthcare Stocks Declared Dividend Raises in 2023
For different reasons, both Eli Lilly and UnitedHealth are doing well enough to enact substantial dividend raises. 
Via The Motley Fool
Move Over, Novo Nordisk -- This Is the Pharmaceutical Company I am Most Bullish On in 2024
Novo Nordisk may dominate the weight management space, but pharma giant Eli Lilly is quickly gaining steam. 
Via The Motley Fool
After Surging 53% in 2023, This Pharmaceutical Stock Might Be About to Crash. Here's Why I'm Probably Wrong
The rise of Ozempic and Wegovy helped Novo Nordisk stock surge over 50% last year. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in 2024
These stocks appear to be on a clear path to continued growth. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
49 50 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.